A Few Good Pouches

The FDA just authorized 11 more nicotine pouches.

That’s on top of 4 more cleared earlier this month. Three weeks ago the total was 30. Today it’s 43.

So what changed?

In September 2025, the FDA launched a pilot program to streamline how it reviews nicotine pouch applications. Same scientific bar. Faster process. Real-time back and forth with applicants instead of a slow-motion paper trail.

It’s working. The first six products under the pilot cleared review in three months. The original pouches authorization took over five years. Twenty-three of the 43 products now on the market came through this pilot alone.

Every one of them went through the same test. The PMTA. Premarket tobacco product application.

And the finding hasn’t moved. Round after round, the FDA’s own review keeps landing on the same conclusion: lower levels of harmful chemicals, some too low to even measure.

Acting CTP Director Bret Koplow put it plainly: rigorous and efficient review are “not mutually exclusive.” 

This is who this is actually for. Adults 21 and older who smoke or use smokeless tobacco. People trying to get off cigarettes completely. The FDA is explicit about that distinction: switching completely is what reduces risk. Dual use doesn’t.

Three weeks ago it was 30. Now it’s 43.

The regulatory system built to protect smokers from bad information is finally moving at a pace that matches how many of them are still lighting up every day.